title: Inhaled nitric oxide versus conventional therapy: effect on oxygenation in ARDS.
abstract: A randomized, controlled clinical trial was performed with patients with acute respiratory distress syndrome (ARDS) to compare the effect of conventional therapy or inhaled nitric oxide (iNO) on oxygenation. Patients were randomized to either conventional therapy or conventional therapy plus iNO for 72 h. We tested the following hypotheses: (1) that iNO would improve oxygenation during the 72 h after randomization, as compared with conventional therapy; and (2) that iNO would increase the likelihood that patients would improve to the extent that the FI(O2) could be decreased by > or = 0.15 within 72 h after randomization. There were two major findings. First, That iNO as compared with conventional therapy increased Pa(O2)/FI(O2) at 1 h, 12 h, and possibly 24 h. Beyond 24 h, the two groups had an equivalent improvement in Pa(O2)/FI(O2). Second, that patients treated with iNO therapy were no more likely to improve so that they could be managed with a persistent decrease in FI(O2) > or = 0.15 during the 72 h following randomization (11 of 20 patients with iNO versus 9 of 20 patients with conventional therapy, p = 0.55). In patients with severe ARDS, our results indicate that iNO does not lead to a sustained improvement in oxygenation as compared with conventional therapy.
authors.affiliation: Department of Medicine, University of Utah School of Medicine, Salt Lake City, USA.
authors.forename: J R
authors.initials: JR
authors.lastname: Michael
authors.forename: R G
authors.initials: RG
authors.lastname: Barton
authors.forename: J R
authors.initials: JR
authors.lastname: Saffle
authors.forename: M
authors.initials: M
authors.lastname: Mone
authors.forename: B A
authors.initials: BA
authors.lastname: Markewitz
authors.forename: K
authors.initials: K
authors.lastname: Hillier
authors.forename: M R
authors.initials: MR
authors.lastname: Elstad
authors.forename: E J
authors.initials: EJ
authors.lastname: Campbell
authors.forename: B E
authors.initials: BE
authors.lastname: Troyer
authors.forename: R E
authors.initials: RE
authors.lastname: Whatley
authors.forename: T G
authors.initials: TG
authors.lastname: Liou
authors.forename: W M
authors.initials: WM
authors.lastname: Samuelson
authors.forename: H J
authors.initials: HJ
authors.lastname: Carveth
authors.forename: D M
authors.initials: DM
authors.lastname: Hinson
authors.forename: S E
authors.initials: SE
authors.lastname: Morris
authors.forename: B L
authors.initials: BL
authors.lastname: Davis
authors.forename: R W
authors.initials: RW
authors.lastname: Day
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D000368:Aged; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000008:administration & dosage* / Q000009:adverse effects; D010100:Oxygen / Q000097:blood*; D012121:Respiration, Artificial; D012128:Respiratory Distress Syndrome / Q000097:blood / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D009569:Nitric Oxide; D010100:Oxygen